Rikos v. Procter & Gamble Co.

782 F. Supp. 2d 522, 74 U.C.C. Rep. Serv. 2d (West) 572, 2011 U.S. Dist. LEXIS 49076, 2011 WL 1707209
CourtDistrict Court, S.D. Ohio
DecidedMay 4, 2011
Docket2:11-mj-00226
StatusPublished
Cited by12 cases

This text of 782 F. Supp. 2d 522 (Rikos v. Procter & Gamble Co.) is published on Counsel Stack Legal Research, covering District Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rikos v. Procter & Gamble Co., 782 F. Supp. 2d 522, 74 U.C.C. Rep. Serv. 2d (West) 572, 2011 U.S. Dist. LEXIS 49076, 2011 WL 1707209 (S.D. Ohio 2011).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART DEFENDANT’S MOTION TO DISMISS (Doc. 10)

TIMOTHY S. BLACK, District Judge.

This civil action is currently before the Court on Defendant’s motion to dismiss (Doc. 10) and the parties’ responsive memoranda (Docs. 15,17).

I. FACTUAL BACKGROUND AS ALLEGED BY PLAINTIFF

This action arises out of alleged misrepresentations made by Defendant in its marketing and sale of a product known as “Align.” Align is a daily food supplement, which Procter & Gamble claims is made of a special formulation of “probiotic” bacteria that builds and maintains a healthy digestive system. P & G states on the product label and in its advertisements that these digestive benefits are clinically and scientifically proven.

Plaintiff alleges that these claims are false and misleading and therefore asserts claims for violation of the Consumers Legal Remedies Act (“CLRA”) (California Civil Code Section 1750, et seq.) and the Unfair Competition Law (“UCL”) (Bus. & Prof.Code Section 17200, et seq.), and breach of express warranty created by P & Gs advertising.

P & G, through a broad based campaign, advertises that Align contains a “Unique Patented Probiotic” that it calls “Bifantis.” (Doc. 9 at ¶ 1). On the Align package, P & G promises that Align will help:

*Build and maintain a healthy digestive system
*Restore your natural digestive balance
^Protect against occasional digestive upsets

(Id. at ¶ 2).

P & G also advertises that Align’s digestive benefits are “clinically proven” and *527 touts Align with its trademarked phrase “GREAT DIGESTION THROUGH SCIENCE.” (Id. at ¶¶ 2, 23, 24). P & G further advertises that Align is “Recommended by Gastroenterologists” and that there is “Proof: Bifantis has been the subject of several clinical studies and has been featured in peer-reviewed journals. Please see Bifantis.com for full details.” (Id. at ¶ 24). On its website, P & G provides purported scientific information and data, including what it calls “Clinical Data Publications,” that P & G claims are proof of the claimed digestive health benefits. (Id. at ¶¶ 35-37).

P & G’s claims are made through a broad based advertising campaign. P & G prominently and conspicuously makes these claims on every Align package, and emphasizes and repeats them through a variety of advertising media including television commercials, point of sale displays, and the Internet. (Id. at ¶ 4).

Plaintiff alleges that the Align label makes claims that are false and misleading. For example, P & G’s own “clinical trial” concluded that there were no statistically significant differences between the control group and the group ingesting the “Bifantis” bacteria, B. Infantis. (Id. at ¶ 36). As to the “Clinical Data Publications,” neither provides proof (clinical or otherwise) of the Align claims. Both studies analyzed patients with irritable bowel syndrome, and not Align’s target audience, the general population. (Id. at ¶ 37). A 2006 study tested endpoints irrelevant to P & G’s advertised claims and tested amounts of the bacteria materially different from the amount in a serving of Align (which the authors stressed was important to the study findings). (Id.) A 2005 study found that those persons receiving the Align bacteria did not experience any improvement in the bowel movement markers. (Id.; see also ¶¶38, 39) (allegations concerning “preclinical data publications” and “review articles” identified by P & G as purported substantiation for its Align claims).

Plaintiff alleges that Align is nothing but sugar-filled capsules injected with a small amount of unremarkable bacteria. Nonetheless, customers pay $30 for a 28-count package. (Id. at ¶ 6). Plaintiff read the claims on the Align label, believed they were true, and purchased Align in reliance on P & G’s advertised claims, expecting that he was paying for a product that had proven digestive health benefits. (Id. at ¶10).

II. STANDARD OF REVIEW

Defendant moves the Court for an order dismissing the amended complaint for lack of subject matter jurisdiction and for failure to state a claim upon which relief may be granted.

A. Fed.R.Civ.P. 12(b)(1)

Federal Rule of Civil Procedure 12(b)(1) provides that an action maybe dismissed for lack of subject matter jurisdiction. Under the Federal Rules, “[p]laintiffs have the burden of proving jurisdiction in order to survive a Rule 12(b)(1) motion.” Weaver v. Univ. of Cincinnati, 758 F.Supp. 446, 448 (S.D.Ohio 1991) (citing Moir v. Greater Cleveland Reg’l. Transit Auth., 895 F.2d 266, 269 (6th Cir.1990)). “The plaintiff bears the burden of establishing, by a preponderance of the evidence, the existence of federal subject matter jurisdiction.” Rogers v. Stratton Indus., Inc., 798 F.2d 913, 915 (6th Cir.1986)

B. Fed.R.Civ.P. 12(b)(6)

A motion to dismiss pursuant to Rule 12(b)(6) operates to test the sufficiency of the complaint.

The first step in testing the sufficiency of the complaint is to identify any conclusory allegations. Ashcroft v. Iqbal, 556 U.S. 662, 129 S.Ct. 1937, 1950, 173 L.Ed.2d *528 868 (2009). “Threadbare recitals of the elements of a cause of action, supported by-mere conclusory statements, do not suffice.” Id. at 1949 (citing Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)). That is, “a plaintiffs obligation to provide the grounds of [her] entitlement to relief requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do.” Twombly, 550 U.S. at 555, 127 S.Ct. 1955. Although the court must accept well-pleaded factual allegations of the complaint as true for purposes of a motion to dismiss, the court is “not bound to accept as true a legal conclusion couched as a factual allegation.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Trader Joe's Tuna Litig.
289 F. Supp. 3d 1074 (C.D. California, 2017)
Garcia v. Kashi Co.
43 F. Supp. 3d 1359 (S.D. Florida, 2014)
Regan v. Sioux Honey Ass'n Cooperative
921 F. Supp. 2d 938 (E.D. Wisconsin, 2013)
In Re Ferrero Litigation
794 F. Supp. 2d 1107 (S.D. California, 2011)
Dremak v. Iovate Health Sciences Group, Inc.
801 F. Supp. 2d 993 (S.D. California, 2011)
In Re Hydroxycut Marketing & Sales Practices Lit.
801 F. Supp. 2d 993 (S.D. California, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
782 F. Supp. 2d 522, 74 U.C.C. Rep. Serv. 2d (West) 572, 2011 U.S. Dist. LEXIS 49076, 2011 WL 1707209, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rikos-v-procter-gamble-co-ohsd-2011.